Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 27;12(11):1770.
doi: 10.3390/jpm12111770.

Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients

Zaira Maraia  1 , Tony Mazzoni  2 , Marco Bruno Luigi Rocchi  3 , Denise Feliciani  4 , Maria Chiara Romani  1 , Giovanna Acciarri  1 , Stefania Rafaiani  4 , Isidoro Mazzoni  4
Affiliations

Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients

Zaira Maraia et al. J Pers Med. .

Abstract

Cytokine patterns and immune activation in patients with Coronavirus 2019 (COVID-19) seem to resemble the case of rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (IBD). Biological drugs, such as anti-tumor necrosis factor α (TNFα) and interleukin (IL) inhibitors, appear to be protective against adverse outcomes of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). However, these treatments are associated with an increased risk of secondary infections. The aim of the study was to examine the association between the use of immunomodulatory drugs and the risk of SARS-CoV-2-associated positivity, hospitalization and death compared to other commonly prescribed treatment regimens among patients with immune-mediated inflammatory diseases.

Methods: All patients with RA, Psoriasis and IBD were included in this observational analysis and treated with anti-TNFα, IL-inhibitors, Methotrexate (MTX) and Sulfasalazine drugs during the year 2020-2021. The population consisted of 932 patients and demographic, clinical and pharmacological data were analyzed.

Results: Although no significant differences were observed between patients treated with biological and synthetic drugs in terms of hospitalization and death, the multivariate logistic model showed that the type of drug influences the possibility of COVID-19 positivity.

Conclusions: The results of this analysis support the use of biological drugs and justify further research investigating the association of these biological therapies with COVID-19 outcomes.

Keywords: COVID-19; IL-inhibitors; SARS-CoV-2; anti-TNFα; death; hospitalization; inflammatory bowel disease; positivity; psoriasis; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Association between COVID-19 positivity and type of drug used.
Figure 2
Figure 2
Association between ARDS hospitalization and comorbidity.
Figure 3
Figure 3
Association between ARDS hospitalization outcome and comorbidity.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA-J. Am. Med. Assoc. 2020;324:782–793. doi: 10.1001/jama.2020.12839. - DOI - PubMed
    1. Azkur A.K., Akdis M., Azkur D., Sokolowska M., Van De Veen W., Brüggen M.-C., O’Mahony L., Gao Y., Nadeau K., Akdis C.A. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–1581. doi: 10.1111/all.14364. - DOI - PMC - PubMed
    1. Jang D.-I., Lee A.-H., Shin H.-Y., Song H.-R., Park J.-H., Kang T.-B., Lee S.-R., Yang S.-H. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int. J. Mol. Sci. 2021;22:2719. doi: 10.3390/ijms22052719. - DOI - PMC - PubMed
    1. de Morales J.M.G.R., Puig L., Daudén E., Cañete J.D., Pablos J.L., Martín A.O., Juanatey C.G., Adán A., Montalbán X., Borruel N., et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun. Rev. 2019;19:102429. doi: 10.1016/j.autrev.2019.102429. - DOI - PubMed
    1. Brembilla N.C., Senra L., Boehncke W.-H. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front. Immunol. 2018;9:1682. doi: 10.3389/fimmu.2018.01682. - DOI - PMC - PubMed

LinkOut - more resources